Oral Fingolimod: MS Exacerbations Continue to Decrease Among Patients in Extended Trial of Oral Fingolimod: Presented at Annual Meeting of the American Neurological Association (ANA)
CHICAGO, IL -- October 11, 2006 -- The number of multiple sclerosis (MS) exacerbations continued to decline in patients who continued on the experimental drug fingolimod and among those placebo patients switched to the drug after conclusion of the original phase 2 trial, researchers reported here at the 131st Annual Meeting of the American Neurological Association (ANA)..."No unexpected adverse events emerged in patients treated up to 24 months compared with the 6-month placebo-controlled phase," said Ludwig Kappos, MD, head, outpatient clinic for neurology/neurosurgery and MS-Research Group, University Hospital, Basel, Switzerland....[Source: Doctor's Guide]